

## DAFTAR PUSTAKA

- Agrawai, A dan Syngal, S., 2009 *Colon Cancer Screening Strategies*, Januari, 2005. <<http://www.medscape.com/viewarticle/497013>> (Diakses: 17 Juni 2015).
- Alsop, K., Mead, L., Smith, L D., Royce, S.G., Tesoriero, A.A., Young, J.P., Haydon, A., Grubb, G., Giles, G.G., Jenkins, M.A., Hopper, J.L., Southey, M.C., 2006, *Low somatic K-ras mutation frequency in colorectal cancer diagnosed under the age of 45 years. European Journal of cancer* 42:1357-1361.
- Andre, T., Boni, C., Navarro, M., *et al.*, 2009, *Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in stage II or III Colon Cancer in the MOSAIC Trial. J.Clin Oncol* 27:3109-3116.
- Asaka, S., Arai, Y., Nishimura, Y., Yamaguchi, K., Ishikubo, T., Yatsuoka., 2009, *T. Microsatellite Instability-low Colorectal Cancer Acquires a K-RAS Mutation During the Progression from Dukes' A to Dukes' B. Carcinogenesis* 30(3);494-499.
- Al-Salama, H.M., Johnstone, E.C., Kerr, D.J., 2009. *What is the Role and Impact of Molecular Markers on Treatment Decision for Colorectal Cancer. Discovery Medicine* 8(42):104-107, October.
- Bahnassy, A.A., Zekri, A.R.N., Haussini, S.E., *et al.*, 2004. *Cyclin A and cyclin D1 as Significant Prognostic Markers in Colorectal Cancer Patients. BMC Gastroenterol* 4:22.
- Iacopetta, B., 2003. *TP53 Mutation in Colorectal Cancer. Hum Mut* 21:271–276.
- Bazan, V., Migliavacca, M., Zanna, I., *et al.*, 2002. *DNA Ploidy and S-phase fraction, but not p53 or NM23-H1 Expression, Predict Outcome in Colorectal Cancer Patients. Result of a 5-year Prospective Study. J Cancer Res Clin Oncol* 128:650-658.
- Benson III, A. B., Schrag, D., Somerfield, M. R., *et al.*, 2004. *American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer. Journal of Clinical Oncology* 22(16):3408-3419.
- Boardman, L.A., Johnson, R.A., Petersen, G.M., *et al.*, 2007. *Higher Frequency of Diploidy in Young-Onset Microsatellite-Stable Colorectal Cancer. Clin Cancer Res* 13(8):2323-2328.
- Breivik, J., Luthe, R.A., Meling, G.I., *et al.*, 1997. *Different Genetic Pathways to Proximal and Distal Colorectal Cancer Influenced by Sex Related Factor. Int J Cancer (Pred Oncol)* 74,664-689.
- Brink, M., de Goeij, A.F.P.M., Weijenberg, M.P., *et al.*, 2003. *K-ras oncogene mutation insporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis* 24(4):703-710.
- Buhmeida, A., Hilska, M., Elzagheid, A., Laato, A., Collan, Y., Syrjänen, K., dan Pyrhönen, S., 2009. *DNA Image Cytometry Predicts Disease Outcome in Stage II Colorectal Carcinoma. Anticancer Research* 29:99-106.

- Buyru, N., Tezol, A., dan Dalay, N., 2006. *Coexistence of K-ras mutation and HPV infection in colorectal cancer. BMC Cancer* 6:115 <<http://www.biomedcentral.com/1471-2407/6/115>> (Diakses: April 2015).
- Cerottini, J.P., Caplin, S., Saraga, E., Givel, J.C., dan Benhattar, J., 1998. *The Type of K-ras Mutation Determines Prognosis in Colorectal Cancer. Am J Surg* 175:198-202.
- Chaubert, P., Benhattar J., Saraga E., dan Costa, J., 1994. *K-ras Mutation and p 53 Alterations in Neoplastic and Nonneoplastic Lesions Associated with Longstanding Ulcerative Colitis. American Journal of Pathology* 144(4):767-775.
- Chiang, J.M., Chou, Y.H.W., Ma S.C., et al., 2004. *Influence of age on adenomatous coli and p53 mutation frequency in sporadic colorectal cancer---rarity of co-occurrence of mutations in APC, K-ras, and p53 genes. Virchows Arch* 445:465-471.
- Compton, C.C., Fielding, P., Burgart, L.,J., et al., 2000. *Prognostic Factors in Colorectal Cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med* 124:979-994.
- Conlin, A., Smith, G., Wolf, F.A., dan Steele, R.J.C., 2005. *The Prognostic Significance of K-ras, p53 and APC mutations in Colorectal Carcinoma. Gut*;54:1283-1286.
- Dahlan, M.S., 2006. *Statistik Untuk Kedokteran dan Kesehatan, seri 1. Seri Evidence Based Medicine*, cetakan ke 2. PT Arkans.
- Dahlan, M.S., 2006. *Besar Sampel dalam Penelitian Kedokteran dan Kesehatan, seri 2. Seri Evidence Based Medicine*, cetakan 1. PT Arkans.
- De Galitiis, F., et al., 2006. *Novel P53 Mutations Detected by FAMA in Colorectal Cancer. An Oncol* 17:78-83.
- Elsaleh, H., Powell, B., McCaul, K., et al., 2001. *P53 Alteration and Microsatellite Instability Have Predictive Value for Survival Benefit from Chemotherapy in Stage III Colorectal Carcinoma. Clinical Cancer Research* 7:1343-1349.
- Figueredo, A., Germond, C., Maroun, J., et al., 1997. *Adjuvant Therapy for Stage II Colon Cancer After Complete Resection. Provincial Gastrointestinal Disease Site Group. Cancer Prev Control* 1(5):379-92.
- Flyger, H.I., Larsen, J.K., Nielsen, H.J., et al., 1999, *DNA Ploidy in Colorectal Cancer, Heterogeneity Within and Between Tumors and Relation to Survival. Cytometry (Communications in Clinical Cytometry)* 38:293-300.
- Franßen, K., Klintonäs, M., Österström, A., Dimberg, J., Monstem, H.J., dan Söderkvist, P., 2004. *Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis* 25(4):527-533.
- Geido, E., Sciutto, A., Rubagotti, A., Oliani, C., et al., 2002. *Combined DNA Flow Cytometry and Sorting With k-ras2 Mutation Spectrum Analysis and the Prognosis of Human Sporadic Colorectal Cancer. Cytometry (Clinical Cytometry)* 50:216-224.

- Ghita, C., Vilcea, I.D., Dumitrescu, M., Vilcea, A.M., Mirea, C.S., Aschie, M., dan Vasilescu, F., 2012. *The prognostic value of the immunohistochemical aspects of tumor suppressor genes p53, bcl-2, PTEN and nuclear proliferative antigen Ki-67 in resected colorectal carcinoma. Rom J Embryol* 53(3):549-56.
- Gilewski, T. dan Norton, L., 1995. *Cytokinetics of Neoplasma. The Molecular Basis of Cancer* 143-159. W.B. Saunders Company.
- Gill, S., Laprinzi, C. L., Sargent, D. J., et al., 2004. *Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much? Jurnal of Clinical Oncology* 22(10):1797-1806.
- Gospodarowicz, M. K., O'Sullivan, dan B., Sobin, L.H., 2006. *Prognostic Factor in Cancer. UICC Third Edition.*
- Graziano, F. dan Cascinu, S., 2003. *Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough? Annals of Oncology* 14:1026-1038.
- Grimes, D.A., Schullz, K.F., 2002, Cohord studies: marching towards outcomes (Epidemiology series). *The Lancet* 359(26):341-345.
- Heimann, T.M., Martinelli, M., Szporn, A., Kurtz, R.J., Quish, A., Miller, F., dan Oh, T.F., 1989. *Prognostic Significance of DNA Content Abnormality in Young Patients with Colorectal Cancer. An Surg* 210(6):792-795. Diunduh dari <http://p53.free.fr> pada bulan Januari 2015.
- Itzkowitz, S. H. dan Yio, X., 2004. *Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am. J. Physiol Gastrointest Liver Physiol* 287:G7-G17.
- Janssen, K. P., Alberici, P., Fsihi, H., et al., 2006. *APC and Oncogenic K-RAS Synergistic in Enhancing Wnt Signaling in Intestinal Tumor Formation and Progression. Gastroenterology* 131:1096-1109.
- Jass, J.R., 2007. *Classification of Colorectal Cancer Based on Correlation of Clinical, Morphological and Molecular Features. Histopathology* 50:113-130.
- Jass, J.R., Mukawa, K., Goh, H.S., Love S.B., dan Capellaro, D., 1989. *Clinical Importance of DNA Content in Rectal Cancer Measured by Flow Cytometry. J Clin Pathol* 42:254-259.
- Karelia, N.H., Patel, D.D., Desai, N.S., et al., 2009. *Prognostic Significance of DNA Aneuploidy and p21 ras Oncoprotein Expression in Colorectal Cancer and Their Role in the Determination of Treatment Modalities. Int J Biol Markers* 16(2):97-104.
- Kouri, M., Pyrhonen, S., Mecklin, J.P., et al., 1990. *The prognostic value of DNA-ploidy in colorectal carcinoma: a prospective study. Br. J. Cancer* 62:976-981.
- Kuebler, I.P., Wieand, H. S., O'Connell, M.,J., 2007. *Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Result From NSABP C-07. Journal of Clinical Oncology* 25(16):2198-2204.

- Labianca, R., Nordlinger, B., Beretta, G.D., *et al.*, 2010, *Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow up. Annals of Oncology* 21 (5):70-77.
- Lacopetta, B., 2003. *TP53 Mutation in Colorectal Cancer. Human Mutation* 21:271-276.
- Lemeshow, S., Hosmer, D.W., Klar, J., Lwanga, S.K., 1993. *Adequacy of Sample Size in Health Studies, Published on behalf of the World Health Organization by John Wiley & Sons, Chichester - New York - Brisbane - Toronto - Singapore.*
- Levin, B., 2006. *Molecular Screening Testing for Colorectal Cancer. Clin Cancer Res* 12(17) September 1:5014-5017.
- Lieberman, D.A., 2009. *Screening for Colorectal Cancer. N Engl J Med* 361:1179-87.
- Locker, G.Y., Hamilton, S., Harris, J., *et al.*, 2006. *ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer. J. Clin. Oncol* 24(33):5313-5327.
- Lynch, H. T. dan Chapelle, A., 2003. *Hereditary Colorectal Cancer. N Engl J Med* 348:919-32.
- Markowitz, S.D., Myeroff L, Cooper, M.J., *et al.*, 1994. *A Benign Cultured Colon Adenoma Bears Three Genetically Altered Colon Cancer Oncogenes, but Progresses to Tumorigenicity and Transforming Growth Factor-Beta independence without Inactivating the p53 Tumor Suppressor Gene. J. Clin. Invest* 93:1005-1013.
- Muleris, M., Chalastanis, A., Meyer, N., *et al.*, 2008. *Chromosomal Instability in Near-Diploid Colorectal Cancer: A Link between Numbers and Structure. <PLoS ONE>.www.plosone.org* 3(2) (Diakses February 2015).
- NCCN, 2008. *Colon Cancer. Practice Guidelines in Oncology - v.1.*
- Ning Su, Xin-Yun Xu, HanChen., Wen-Chao Gao, Can-Ping Ruan, Qiang Wang, dan Yan-Ping Sun., 2010. *Increased Expression of Annexin A1 Is Correlated with K-Ras Mutation in Colorectal Cancer. Tohoku J. Exp. Med* 222:243-250.
- Notarnicola, M., Cavallini, A., Cardone, R., Pepzola, F., Demma, I., dan Di Leo, A., 2000. *K-ras and p53 Mutation in DNA Extracted from Colonic Epithelial Cell Exfoliated in Faeces of Patients with Colorectal Cancer. Digest liver dis* 32:131-6.
- Ogino, S., Meyerhardt., J.A., dan Irahara, N., 2009. *K-RAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALB GB 89803. Clin Cancer Res* 15(23):7322-9.
- Okulczyk, B., Kovalchuk, O., Piotrowski, Z., *et al.*, 2004. *Clinical usefulness of K-RAS mutation detection in colorectal cancer and in surgical margins of the colon. Annales Academiae Medicae Bialostocensis* 49(1):52-54.
- Palmirotta, R., Savonarola, A., dan Ludovici, G., 2011. *Concurrent mutation in exon 1 and 2 of the K-ras oncogene in colorectal cancer. Folia Histochemica Et Cytobiologica* 49(4):729-733.

- Paluszkiwicz, P., Berbec, H., Palwowska-Wakowicz, B., Cybulski, M., dan Paszkowska, A., 2004. *p53 protein accumulation in colorectal cancer tissue has prognostic value only in left-sided colon tumours. Cancer Detection and Prevention* 28;252-259.
- Park, Y. J., Mitrou, P. N., Luben, R., Khaw, K. T., dan Bingham, S. A., 2009. *Is bowel habit linked to colorectal cancer? – Results from the EPIC-Norfolk study. European Journal of Cancer* 45:139-145.
- Pidato Pengukuhan Jabatan Guru Besar Tetap dalam Bidang Ilmu Penyakit Dalam pada Fakultas Kedokteran Universitas Sumatera Utara, Medan, 2007. *Deteksi Dini dan Penatalaksanaan Kanker Usus Besar*, Siregar, G.A., Fakultas Kedokteran Universitas Sumatera Utara.
- Rhonda, K.Y., Mahmoud, G., Xi, K.Z, *et al.*, 2009. *Clinical, Pathologic, and Molecular Features of Early-onset Colorectal Carcinoma. Am J Surg Pathol* 33:572-582.
- Robertson, D.J., Dominitz, J.A., 2014. *Stool DNA and Colorectal-Cancer Screening. N Engl J Med* 370;14:1350-1351.
- Rodrigues, N.,R., Rowan, A., Smith, M.,E.,F, *et al.*, 1990, *P53 Mutations in Colorectal Cancer. Proc. Natl. Acad. Sci USA* 87:7555-7559.
- Roth, A., D., Tejpar, S., Delorenzi, M., 2010, *Prognostic Role of K-RAS and BRAF in stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORT 40993, SAKK 60-00 Trial. Journal of Clinical Oncology* 28(3):466-474.
- Russo, A., Bazan, V., Lacopetta, B., *et al.*, 2005. *The TP53 Colorectal Cancer International Collaborative Study on yhr Prognostic and Predictive Sygnificance of p53 Mutation: Influence of Tumor Site, Type of Mutation, and Adjuvant Treatment. Journal of Clinical Oncology* 23(30):2518-2528.
- Russo, A., Migliavacca, M., Zanna, I., *et al.*, 2002. *p53 Mutations in L3-Loop Zinc-binding Domain, DNA Ploidy, and S phase Fraction Are Independent Prognostic Indicators in Colorectal Cancer: A Prospective Study with a Five-Year Follow-Up. Cancer Epidemiology, Biomarkers & Prevention* 11:1322-1331.
- Saif, M. W. dan Shah, M., 2009. *K-Ras Mutation in Colorectal Cancer: A Practice Changing Discovery. Clinical Advances in Hematology & Oncology* 7(1):45-54.
- Sarasqueta, A.,F., Forte, G.,I., Corver, W.,E., *et al.*, 2013. *Integral Analysis of p53 and Its Value as Prognostic Factor in Sporadic Colon Cancer. BMC Cancer* 13:277-288.
- Sastroasmoro, S. dan Ismael, S., 2002. *Dasar-Dasar Metodologi Penelitian Klinis Edisi ke-2*. CV Sagung Seto.
- Shackelford, R.E., Kaufmann, W.K., dan Paules, R.S., 1999. *Cell Cycle Control, Checkpoint Mechanisms and Genotoxic Stress. Environmental Health Perspectives Vol. 107, Supplement 1: Reviews in Environmental Health Feb, pp. 5-24.*
- Shapiro, G.I., 2006. *Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment. Journal of Clinical Oncology* 24(11):1770-1783.

- Smith, G., Carey, F.A., Beattie, J., *et al.*, 2002. *Mutation in APC, Kirsten-ras, and p53-alternative genetic pathways to colorectal cancer*. PNAS 99:(14):9433-9438.
- Tang, R., Wang, J.Y., Fan, C.W., Tsao, K.C., Chen, H.H., Wu, C.M., Chen, J.S., Changchien, C.R., dan Hsieh, L.L., 2004. *p53 is an independent pre-treatment marker for long-term survival in stage II and III colorectal cancer: an analysis of interaction between genetic markers an fluorouracil-based adjuvant therapy*. *Cancer Letter* 210; 101-109. *The First Annual National Cancer Center Symposium. Kanker Kolorektal Di Rumah Sakit Kanker Dharmais Tahun 1994-2003*. Ajoedi., 2004.
- TimJa Hati dan Sal Cerna, 2008. *Panduan Penatalaksanaan Kanker Hati dan Saluran Cerna*. April.
- Torsello, A., Garufi, C., Cosimelli, M., Diodoro, M.G., Zeuli, M., Vanni, B., Campanella, C., D'Angelo, C., Sperduti, I., Donnorso, R.P., Cognetti, F., Terzoli, E., dan Mottolese, M., 2008. *p53 and bcl-2 in colorectal cancer arising in patients under 40 years of age: Distribution and prognostic relevance*. *European Journal of Cancer* 44;1217-1222.
- Tortola, S., Marcuello, E., Gonzales, I., *et al.*, 1999. *p53 and K-ras Gene Mutations correlate With Tumor Aggressiveness But Are Not of Routine Prognostic Value in Colorectal Cancer*. *Journal of Clinical Oncology* 17(5):1375-1381.
- Twelves, C., Wong, A., Nowacki, M., P., *et al.*, 2005. *Capecitabine as Adjuvant Treatment for Stage III Colon Cancer*. *N.Engl.J.Med* 352;26:2696-2704.
- Van Geelen, C.M.M., de Vries, E.G.E., de Jong, S., 2004. *Lessons from TRAIL-resistance mechanisms in Colorectal Cancer Cells: Paving the Road to Patient-tailored Therapy*. *Drug Resistance Updates* 7:345-358.
- Wang, H.Y., Jin, S., Xue, Z.Q., *et al.*, 2001. *Prognostic Significance of DNA Ploidy in Patients with Stage II Colorectal Cancer*. *Chinese Journal of Cancer Research* 13(1):53-56.
- Zulhabri, O., Rahman, J., Ismail, S., Isa, M.R., Wan Zurinah, W.N. 2012. *Predominance of G to A kodon mutation K-ras gene in Dukes' B colorectal cancer*. *Singapore Med J* 53(1):26-31.